It's not hard to see why family offices can be a problem. Big-time investors are supposed to be putting their clients' interests first, and The Journal report suggests that if they're investing for themselves, they might get distracted from their work.
Worse yet, their personal investments could pose a conflict for their firms.
Bill Ackman's example, however, stands out, in part because it's linked to one of the biggest business scandals in recent years, the fall of Valeant Pharmaceuticals.
Ackman has a fraught relationship with the company. He backed its bid to acquire Allergan, the maker of Botox, in 2014, which ultimately failed. A year later, Ackman's Pershing Square fund bought a stake in it and rode the stock down through its dramatic 90% collapse until last month, when Ackman finally threw in the towel.
During that time, The Journal notes, Ackman made a personal investment ($7 million for a 1.5% stake) in Sprout, the maker of a libido pill for women, called Addyi, in 2015. Valeant eventually bought Sprout, and Sprout apparently sought Ackman's guidance on the matter, according to The Journal.
He assured the company that Valeant's management was top-notch (most of them have since been fired, including the CEO), and Valeant picked up Sprout for $1 billion because of Addyi. Not a bad payday for Ackman.
The problem is that Addyi has been a massive failure for Valeant. According to experts, it just doesn't work.
So while this was a good deal for Ackman, it was a raw deal for Valeant and its shareholders, including Pershing Square and its clients.
"Mr. Ackman told Pershing Square shareholders he had played no role in Valeant's decision to acquire Sprout. His economic interest in Pershing Square was larger than his interest in Sprout, said a person familiar with his holdings.
So according to the Journal, Ackman's personal investment paid off nicely, while his fund's shareholders ended up getting burned.
Source: WSJ
Junior Trader Ivan Ivanov
Read more:
25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256
World Financial Markets - 0700 17 600 Varchev Exchange - 0700 115 44
Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.
Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006
The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
Disclaimer:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.